APPLICATIONS PUBLISHED 15 OCTOBER 2003
Published: 1-Mar-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
A method for the preparation of nanoparticles
Orion Corp 1351666*
Pharmaceutical formulation containing citalopram
H Lundbeck 1351667*
Sustained release pharmaceutical dosage forms with minimised pH dependent dissolution profiles
Shire Laboratories 1351668*
Clear propofol compsns
Bherat Serums & Vaccines 1351669*
Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
Neuromolecular 1351670*
Triphenylmethane kinasin inhibitors
Cytokinetics 1351671*
Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
Thia Medica 1351672*
Compsns of stable T3? and methods of use thereof
Resuscitek 1351673*
Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
Cornell Research Foundation 1351674*
Alpha-difluoromethylornithine (DFMO) use in the human prostate
The Regents of the University of California; The Arizona Board of Regents on behalf of the University of Arizona 1351675*
Use of isovaleryl L-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis
Sigma-Tau Industrie Farmaceutiche Riunite 1351676*
Method for treating cancer
Bionumerik Pharmaceuticals 1351677*
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
Shanahan-Prendergast, Elizabeth 1341678*
Method and compsn for the treatment of diabetic neuropathy
The Quigley Corp 1351679*
Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
Solvay Pharma 1351680*
Implantable device containing resorbable matrix material and antiproliferative drugs for preventing or treating failure of haemodialysis vascular access and other vascular grafts
Vascular Therapies 1351681*
Regulation of lipids and/or bone density and compsns thereof
Novogen Research 1351682*
Combination comprising and AT1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
Novartis 1351683*
Compounds and methods for promoting smoking cessation
Research Triangle Institute 1351684*
Stabilised formulation of selective ligands of retinoic acid gamma-receptors
Johnson & Johnson Consumer Products 1351685*
Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
Pharmacia Corp 1351686*
Urotensin-II receptor antagonists
SmithKline Beecham 1351687*
Urotensin-II receptor antagonists
SmithKline Beecham 1351688*
Derivatives of the (3S, 4AR, 6S, 8AR) 6-phenylamino-1,2,3,4,4A,5,6,7,8,8A-decahydroisoquinoline-3-carboxylic acid as excitatory amino acid receptor antagonists for the treatment of neurological disorders and neurodegenerative diseases
Eli Lilly 1352689*
Method for treatment of dopamine-related dysfunction through administration of full D1 dopamine receptor agonist with no induction of tolerance
Purdue Research Foundation; University of North Carolina at Chapel Hill 1351690*
Substituted 2-aryl-4-arylaminopyrimidines and analogues as activators of caspases and inducers of apoptosis and the use thereof
Cytovia 1351691*
Oral formulation comprising an inhibitor compound of the ileal bile transport and an HMG Co-A reductase inhibitor
AstraZeneca 1351692*
Novel method and compsns for local treatment of Meniere's disease, tinnitus and/or hearing loss
Synphora 1351693*
Promoting cell regeneration and/or cell differentiation with non-metabolisable sugar and a polymeric absorbent
Lmd 1351694*
Camptothecin compounds with a sulphylhydryl group
Research Triangle Institute; Duke University; National Institutes of Health 1351695*
Compsn for the delivery of haematopoietic growth factor
Rxkinetix 1351696*
Pharmaceutical for stimulating the regeneration of tissues
Watzek, Georg; Gruber, Reinhard; Bio-Products and Bio-Engineering Aktiengesellschaft 1351697*
Herbal compsn for angina pectoris, method to prepare same and uses thereof
Tianjin Tasly Pharmaceutical 1351698*
Methods for improved diagnosis and treatment of mycobacterial infections
Zhang, Ying 1351699*
Conjugates of nucleosides with lactosaminated human albumine
Universita di Bologna 1351700*
Active metabolite of antifungal compound
Merck 1351701*
Trem-1 splice variant for use in modifying human responses
Baylor College of Medicine 1351702*
Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation
ZymoGenetics 1351703*
Storage stable powder compsns of interleukin-4 receptor
Nektar Therapeutics 1351704*
Compsns for treatment of haemorrhaging with activated factor VIIA in combination with fibrinogen
US Army Medical Research and Materiel Command 1351705*
Method for treating haemophilia B
ZymoGenetics 1351706*
Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
Baylor Research Institute 1351707*
Therapeutic agent comprising a B-subunit of a protein toxin
University of Bristol 1351708*
Pegylation of linkers improves antitumour activity and reduces toxicity of immunoconjugates
The Government of the United States of America, as represented by the Department of Health and Human Services 1351709*
Compsns containing inclusion complexes
California Insitute of Technology; Insert Therapeutics 1351710*
Generation and/or reduction of new lung tissue in an affected lung, by modulation of the WNT pathway
Academisch Ziekenhuis Leiden 1351711*
Targeted combination immunotherapy of cancer and infectious diseases
Immunomedics 1351712*
Anti-tenascin monoclonal antibody therapy for lymphoma
Duke University 1351713*
